West Pharmaceutical Services, Inc.

What they do

West designs and produces primary packaging such as stoppers, seals, syringe and cartridge components, vials, plungers, and reconstitution and transfer systems, plus self-injection and drug delivery devices. It also provides analytical lab services, sterilization, washing, vision inspection, and integrated solutions. Its West Vantage segment (renamed from Contract-Manufactured Products effective Q1 2026) makes complex devices and performs automated assembly, combination product assembly, and packaging. Customers are primarily biologic, generic, pharmaceutical, diagnostic, and medical device companies.

Revenue drivers

• High-Value Product (HVP) Components — Proprietary Products packaging such as stoppers, seals and syringe/cartridge components. Q2 2026 net sales were $424.1 million, up 19.4% reported and 18.4% organic, and accounted for 49% of total company net sales.
• HVP Delivery Devices — Self-injection and delivery devices including SmartDose. Q2 2026 net sales were $131.2 million, up 29.6% reported and 29.2% organic, 15% of total company net sales.
• Standard Products — Lower-value primary packaging. Q2 2026 net sales were $167.3 million, up 2.4% reported and 0.7% organic, 19% of total company net sales.
• West Vantage — Contract manufacturing and automated assembly of complex devices and combination products. Q2 2026 net sales were $149.7 million, up 2.0% reported and 0.8% organic, 17% of total company net sales.

Recent performance

Second-quarter 2026 net sales were $872.3 million, up 13.8% reported and 12.7% organic. Diluted EPS was $2.15, up 18.1%, and adjusted-diluted EPS was $2.37, up 28.8%. Operating cash flow was $213.9 million and capital expenditures were $85.9 million, giving free cash flow of $128.0 million. Proprietary Products net sales rose 16.6% to $722.6 million while West Vantage rose 2.0% to $149.7 million. For the first six months of 2026 the company repurchased 1.8 million shares for $454.3 million at an average price of $258.03.

Strategy

Management attributes growth to HVP Components, strength in Biologics, a mix shift from HVP upgrades including Annex 1, and GLP-1 elastomers. The company is investing in capital spending guided at $250 million to $275 million for 2026. It renamed the Contract-Manufactured Products segment to West Vantage effective Q1 2026 to align with its current strategic focus and offerings, with no change to segment composition or prior reported segment information. It continued share repurchases under a program announced in mid-February 2026 and pays a quarterly dividend, declared at $0.22 per share for Q3 2026.

Risks

• Tariffs and trade restrictions — The 10-K notes U.S. tariffs and trade restrictions imposed beginning in 2025 and reciprocal measures by other jurisdictions, though the impact was not material to 2025 results and the company does not expect a material impact on 2026 results.
• Customer concentration in biologics and generics — Proprietary Products sales are primarily to biologic, generic, and pharmaceutical drug customers, leaving results sensitive to demand and ordering timing in those end markets.
• Customer-controlled demand timing — The 10-K lists timing of orders and shipments, regulatory actions, and competition among factors affecting reported net sales in any period.
• Foreign currency exposure — Non-U.S. sales were 56.7% of consolidated net sales in 2025, and guidance includes an estimated currency benefit of about 1 percentage point for full-year 2026 and a roughly 1 percentage point headwind for Q3 2026.

Outlook

Full-year 2026 net sales guidance was raised to $3.345 billion to $3.380 billion, up 8.8% to 10.0% reported and 10.0% to 11.0% organic, from a prior $3.295 billion to $3.350 billion. Full-year 2026 adjusted-diluted EPS guidance was increased to $8.85 to $9.05 from $8.40 to $8.75. Third-quarter 2026 net sales are guided to $820 million to $835 million with adjusted-diluted EPS of $2.14 to $2.24. Capital spending guidance is unchanged at $250 million to $275 million.